Literature DB >> 15297424

CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma.

Delia Mezzanzanica1, Emanuela Balladore, Fabio Turatti, Elena Luison, Paola Alberti, Marina Bagnoli, Mariangela Figini, Alessandra Mazzoni, Francesco Raspagliesi, Maria Oggionni, Silvana Pilotti, Silvana Canevari.   

Abstract

PURPOSE: Ovarian carcinoma is a highly lethal malignancy that often becomes resistant to chemotherapy. Alterations in apoptotic signals and p53 status contribute to drug resistance, and CD95-mediated apoptosis is also deficient in resistant cells. We analyzed the mechanism of resistance to CD95-mediated apoptosis in ovarian carcinoma cell lines differing in p53 status. EXPERIMENTAL
DESIGN: CD95-mediated apoptosis was induced by agonistic anti-CD95 antibody, and the apoptotic cascade was monitored with biochemical and functional assays.
RESULTS: CD95-mediated apoptosis was blocked in human ovarian cancer cells. In cell lines with wild-type p53, treatment with the protein synthesis inhibitor cycloheximide (CHX) together with anti-CD95 overcame the resistance, suggesting the presence of a labile inhibiting protein. Indeed, the labile protein cellular FLICE-inhibitory protein long form (c-FLIP(L)) was found to block caspase-8 recruitment to the death-inducing signaling complex (DISC), and sensitization of cells by CHX was due to c-FLIP(L) down-modulation at the DISC level. Down-regulation of c-FLIP(L) with antisense oligonucleotides increased CD95-mediated apoptosis as in cells sensitized by CHX, demonstrating the direct involvement of c-FLIP(L) in apoptosis resistance. Removal of c-FLIP(L) block at DISC level allowed full activation of the mitochondrial pathway and, eventually, apoptosis in wild-type p53 cells, whereas in cells with mutated p53, c-FLIP(L) involvement in CD95-mediated apoptosis resistance appeared to be irrelevant. Immunohistochemical analysis of an ovarian tumor tissue array revealed c-FLIP(L) expression in samples with no p53 accumulation (P = 0.034), and a significant (P = 0.037) inverse relationship between c-FLIP(L) and p53 expression levels was also observed in 27 epithelial ovarian cancer specimens with known p53 status.
CONCLUSION: The inhibitory protein c-FLIP(L) is involved in resistance to CD95-mediated apoptosis in ovarian carcinoma cells with wild-type p53.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15297424     DOI: 10.1158/1078-0432.CCR-03-0537

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  14 in total

1.  Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells.

Authors:  Egidio Iorio; Alessandro Ricci; Marina Bagnoli; Maria Elena Pisanu; Giancarlo Castellano; Massimo Di Vito; Elisa Venturini; Kristine Glunde; Zaver M Bhujwalla; Delia Mezzanzanica; Silvana Canevari; Franca Podo
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

2.  Thalidomide potentiates etoposide-induced apoptosis in murine neuroblastoma through suppression of NF-κB activation.

Authors:  Tomomasa Hiramatsu; Jyoji Yoshizawa; Kazuaki Miyaguni; Tetsuro Sugihara; Atsushi Harada; Sayuri Kaji; Goki Uchida; Daisuke Kanamori; Yuji Baba; Shuichi Ashizuka; Takao Ohki
Journal:  Pediatr Surg Int       Date:  2018-02-08       Impact factor: 1.827

3.  Targeted ovarian cancer treatment: the TRAILs of resistance.

Authors:  Nadzeya Goncharenko Khaider; Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  Am J Cancer Res       Date:  2011-11-21       Impact factor: 6.166

4.  Human GM3 Synthase Attenuates Taxol-Triggered Apoptosis Associated with Downregulation of Caspase-3 in Ovarian Cancer Cells.

Authors:  Su Huang; Khadijeh Bijangi-Vishehsaraei; Mohammad Reza Saadatzadeh; Ahmad R Safa
Journal:  J Cancer Ther       Date:  2012-10

Review 5.  Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy.

Authors:  Ahmad R Safa; Travis W Day; Ching-Huang Wu
Journal:  Curr Cancer Drug Targets       Date:  2008-02       Impact factor: 3.428

6.  Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells.

Authors:  J C Symes; C Siatskas; D H Fowler; J A Medin
Journal:  Cancer Gene Ther       Date:  2008-12-19       Impact factor: 5.987

7.  c-FLIP knockdown induces ligand-independent DR5-, FADD-, caspase-8-, and caspase-9-dependent apoptosis in breast cancer cells.

Authors:  Travis W Day; Su Huang; Ahmad R Safa
Journal:  Biochem Pharmacol       Date:  2008-09-17       Impact factor: 5.858

Review 8.  FLIP as an anti-cancer therapeutic target.

Authors:  Jin Kuk Yang
Journal:  Yonsei Med J       Date:  2008-02-29       Impact factor: 2.759

9.  Expression and biological significance of c-FLIP in human hepatocellular carcinomas.

Authors:  Xilin Du; Guoqiang Bao; Xianli He; Huadong Zhao; Fang Yu; Qing Qiao; Jianguo Lu; Qingjiu Ma
Journal:  J Exp Clin Cancer Res       Date:  2009-02-20

Review 10.  Lesser-Known Molecules in Ovarian Carcinogenesis.

Authors:  Ludmila Lozneanu; Elena Cojocaru; Simona Eliza Giuşcă; Alexandru Cărăuleanu; Irina-Draga Căruntu
Journal:  Biomed Res Int       Date:  2015-08-03       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.